News for Horizon Pharma Stock (HZNP)

Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference

Business Wire • 06/06/22

Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference

Business Wire • 06/02/22

Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy

Business Wire • 06/01/22

Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund

Business Wire • 05/31/22

Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

Business Wire • 05/31/22

Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology

Business Wire • 05/24/22

Horizon (HZNP) Begins Enrollment in Alopecia Areata Study

Zacks Investment Research • 05/18/22

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata

Business Wire • 05/17/22

Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups

Business Wire • 05/16/22

Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen's Association 2022 Rising Star

Business Wire • 05/11/22

Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On

Business Wire • 05/11/22

Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership

Business Wire • 05/09/22

Horizon: For Those Who Dare

Seeking Alpha • 05/09/22

Horizon (HZNP) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

Zacks Investment Research • 05/05/22

Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q1 2022 Results - Earnings Call Transcript

Seeking Alpha • 05/04/22

Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Beat Estimates

Zacks Investment Research • 05/04/22

Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results

Business Wire • 05/04/22

HZNP or TECH: Which Is the Better Value Stock Right Now?

Zacks Investment Research • 05/03/22

Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis

Business Wire • 05/03/22

Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community

Business Wire • 05/02/22

Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation

Benzinga • 05/02/22

Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Business Wire • 05/02/22

Horizon Therapeutics (HZNP) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research • 04/27/22

Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide

Business Wire • 04/27/22

Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community

Business Wire • 04/19/22